Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer.
Petrelli A, Bellomo SE, Sarotto I, Kubatzki F, Sgandurra P, Maggiorotto F, Di Virgilio MR, Ponzone R, Geuna E, Galizia D, Nuzzo AM, Medico E, Miglio U, Berrino E, Venesio T, Ribisi S, Provero P, Sapino A, Giordano S, Montemurro F. Petrelli A, et al. Among authors: sapino a. ESMO Open. 2020 Oct;5(5):e000937. doi: 10.1136/esmoopen-2020-000937. ESMO Open. 2020. PMID: 33122354 Free PMC article.
[Standardized pathological reporting for tumors].
Abbona GC, Papotti M, Montemurro F, Viberti L, Sapino A, Bussolati G. Abbona GC, et al. Among authors: sapino a. Pathologica. 1997 Oct;89(5):546-65. Pathologica. 1997. PMID: 9489404 Italian. No abstract available.
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study.
Sapino A, Montemurro F, Marchiò C, Viale G, Kulka J, Donadio M, Bottini A, Botti G, dei Tos AP, Bersiga A, Di Palma S, Truini M, Sanna G, Aglietta M, Bussolati G. Sapino A, et al. Ann Oncol. 2007 Dec;18(12):1963-8. doi: 10.1093/annonc/mdm417. Epub 2007 Sep 4. Ann Oncol. 2007. PMID: 17785760 Free article.
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Montemurro F, Redana S, Viale G, Sanna G, Donadio M, Valabrega G, del Curto B, Bottini A, Botti G, dei Tos AP, Jacomuzzi ME, Di Bonito M, Danese S, Clavarezza M, Kulka J, Di Palma S, Durando A, Sapino A, Aglietta M. Montemurro F, et al. Among authors: sapino a. Clin Breast Cancer. 2008 Oct;8(5):436-42. doi: 10.3816/CBC.2008.n.053. Clin Breast Cancer. 2008. PMID: 18952558
Underuse of anthracyclines in women with HER-2+ advanced breast cancer.
Montemurro F, Rossi V, Nolè F, Redana S, Donadio M, Martinello R, Verri E, Valabrega G, Rocca MC, Jacomuzzi ME, Viale G, Sapino A, Aglietta M. Montemurro F, et al. Among authors: sapino a. Oncologist. 2010;15(7):665-72. doi: 10.1634/theoncologist.2010-0016. Epub 2010 Jun 24. Oncologist. 2010. PMID: 20576644 Free PMC article.
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F. Valabrega G, et al. Among authors: sapino a. Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9. Breast Cancer Res Treat. 2011. PMID: 21153051
408 results